The role of Stratus OCT in anti-VEGF therapy.: Qualitative and quantitative assessment of neovascular AMD

被引：13

作者：

Bolz, M. ^{[1
]}

Ritter, M. ^{[1
]}

Polak, K. ^{[1
]}

Ahlers, C. ^{[1
]}

Hirn, C. ^{[1
]}

Pruente, C. ^{[1
]}

Golbaz, I. ^{[1
]}

Benesch, T. ^{[2
]}

Schmidt-Erfurth, U. ^{[1
]}

机构：

[1] Med Univ Wien, Univ Klin Augenheilkunde & Optometr, A-1090 Vienna, Austria

[2] Med Univ Wien, Inst Med Stat, Besondere Einrichtung Med Stat & Informat, A-1090 Vienna, Austria

来源：

OPHTHALMOLOGE | 2008年 / 105卷 / 07期

关键词：

age-related macular degeneration (AMD); optical coherence tomography (OCT); anti-VEGF therapy; ranibizumab; segmentation;

D O I：

10.1007/s00347-007-1639-1

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Background The evaluation of OCT3 during anti-VEGF therapy. Methods A total of 29 patients with choroidal neovascularization secondary to AMD received 3 intravitreal injections of ranibizumab. OCT examination and visual acuity testing (ETDRS) were performed before therapy onset, after 1 week and after 1, 2 and 3 months. Results The central retinal thickness (CRT) was assessed correctly by OCT in 128 out of 145 measurements. There was a distinct (84%) but not significant correlation between decrease in central retinal thickness and increase in visual acuity. Incorrect retinal layer segmentation and inadequate CRT measurements were a significant technical limitation. Conclusion During anti-VEGF therapy, OCT allows documentation and quantification of morphologic retinal changes and in most cases also for an estimation of functional improvement.

引用

页码：650 / 655

页数：6

共 15 条

[1]

Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621

[2] Vascular endothelial growth factor: Basic science and clinical progress [J].

Ferrara, N .

ENDOCRINE REVIEWS, 2004, 25 (04) :581-611

[3]

GOHDES DM, 2005, PREV CHRONIC DIS, V3, pA17

[4]

Gürses-Özden R, 2004, J GLAUCOMA, V13, P238

[5]

Heier JS, 2006, OPHTHALMOLOGY, V113, pe1

[6] The epidemiology of age-related macular degeneration [J].

Klein, R ;

Peto, T ;

Bird, A ;

Vannewkirk, MR .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2004, 137 (03) :486-495

[7]

Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338

[8]

Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855

[9] Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following lntravitreal administration [J].

Mordenti, J ;

Cuthbertson, RA ;

Ferrara, N ;

Thomsen, K ;

Berleau, L ;

Licko, V ;

Allen, PC ;

Valverde, CR ;

Meng, YG ;

Fei, DTW ;

Fourre, KM ;

Ryan, AM .

TOXICOLOGIC PATHOLOGY, 1999, 27 (05) :536-544

[10] Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes [J].

Otani, A ;

Takagi, H ;

Oh, H ;

Koyama, S ;

Ogura, Y ;

Matumura, M ;

Honda, Y .

MICROVASCULAR RESEARCH, 2002, 64 (01) :162-169

← 1 2 →